NASDAQ:ACHN - Achillion Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.99 +0.02 (+0.67 %)
(As of 06/18/2018 04:00 PM ET)
Previous Close$2.99
Today's Range$2.90 - $3.01
52-Week Range$2.58 - $5.66
Volume856,770 shs
Average Volume1.66 million shs
Market Capitalization$410.87 million
P/E Ratio-4.82
Dividend YieldN/A
Beta0.86

About Achillion Pharmaceuticals (NASDAQ:ACHN)

Achillion Pharmaceuticals logoAchillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trial; ACH-5548, a factor D inhibitor; and other factor D inhibitors. It has license agreements with GCA Therapeutics, Ltd and Ora, Inc., as well as a collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize drug candidates for the treatment of chronic hepatitis C virus. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

Receive ACHN News and Ratings via Email

Sign-up to receive the latest news and ratings for ACHN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ACHN
CUSIP00448Q20
Phone203-624-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio38.07
Quick Ratio38.07

Price-To-Earnings

Trailing P/E Ratio-4.82
Forward P/E Ratio-5.34
P/E GrowthN/A

Sales & Book Value

Annual Sales$15 million
Price / Sales27.58
Cash FlowN/A
Price / CashN/A
Book Value$2.35 per share
Price / Book1.27

Profitability

EPS (Most Recent Fiscal Year)($0.62)
Net Income$-85,230,000.00
Net MarginsN/A
Return on Equity-25.57%
Return on Assets-24.65%

Miscellaneous

Employees88
Outstanding Shares138,340,000

Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions

What is Achillion Pharmaceuticals' stock symbol?

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) released its quarterly earnings data on Wednesday, May, 2nd. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.01. View Achillion Pharmaceuticals' Earnings History.

When is Achillion Pharmaceuticals' next earnings date?

Achillion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Achillion Pharmaceuticals.

What price target have analysts set for ACHN?

7 brokerages have issued 12 month price targets for Achillion Pharmaceuticals' stock. Their forecasts range from $3.50 to $7.00. On average, they expect Achillion Pharmaceuticals' stock price to reach $5.00 in the next twelve months. View Analyst Ratings for Achillion Pharmaceuticals.

Who are some of Achillion Pharmaceuticals' key competitors?

Who are Achillion Pharmaceuticals' key executives?

Achillion Pharmaceuticals' management team includes the folowing people:
  • Dr. Milind S. Deshpande, CEO & Director (Age 61)
  • Mr. Joseph Truitt, Pres & COO (Age 53)
  • Ms. Mary Kay Fenton, Exec. VP, CFO & Principal Accounting Officer (Age 54)
  • Glenn Schulman, Exec. Director of Investor Relations
  • Ms. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 63)

Has Achillion Pharmaceuticals been receiving favorable news coverage?

Headlines about ACHN stock have trended somewhat positive on Monday, Accern reports. The research group identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a news sentiment score of 0.18 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 45.04 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Achillion Pharmaceuticals' major shareholders?

Achillion Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.46%), Dimensional Fund Advisors LP (4.37%), Northern Trust Corp (1.14%), Opaleye Management Inc. (0.79%), JPMorgan Chase & Co. (0.75%) and DAFNA Capital Management LLC (0.63%). Company insiders that own Achillion Pharmaceuticals stock include & Johnson Johnson, Jason S Fisherman, Joel C Barrish and Mary Kay Fenton. View Institutional Ownership Trends for Achillion Pharmaceuticals.

Which institutional investors are selling Achillion Pharmaceuticals stock?

ACHN stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, JPMorgan Chase & Co., DAFNA Capital Management LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Achillion Pharmaceuticals.

Which institutional investors are buying Achillion Pharmaceuticals stock?

ACHN stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Opaleye Management Inc., Candriam Luxembourg S.C.A., UBS Group AG, Schwab Charles Investment Management Inc., BlackRock Inc., Northern Trust Corp and A.R.T. Advisors LLC. Company insiders that have bought Achillion Pharmaceuticals stock in the last two years include Jason S Fisherman, Joel C Barrish and Mary Kay Fenton. View Insider Buying and Selling for Achillion Pharmaceuticals.

How do I buy shares of Achillion Pharmaceuticals?

Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achillion Pharmaceuticals' stock price today?

One share of ACHN stock can currently be purchased for approximately $2.99.

How big of a company is Achillion Pharmaceuticals?

Achillion Pharmaceuticals has a market capitalization of $410.87 million and generates $15 million in revenue each year. The biopharmaceutical company earns $-85,230,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Achillion Pharmaceuticals employs 88 workers across the globe.

How can I contact Achillion Pharmaceuticals?

Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.


MarketBeat Community Rating for Achillion Pharmaceuticals (ACHN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  390 (Vote Outperform)
Underperform Votes:  290 (Vote Underperform)
Total Votes:  680
MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACHN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.